Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned a consensus recommendation of “Moderate Buy” from the twenty research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $981.71.

A number of brokerages recently commented on REGN. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Bank of America boosted their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd.

Insiders Place Their Bets

In related news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the sale, the executive vice president now owns 37,543 shares in the company, valued at approximately $36,328,483.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joseph J. Larosa sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the sale, the executive vice president now directly owns 37,543 shares of the company’s stock, valued at $36,328,483.95. The disclosure for this sale can be found here. Insiders have sold a total of 8,095 shares of company stock valued at $7,779,766 over the last 90 days. 8.83% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $932,571,000. FMR LLC increased its stake in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares during the period. International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after buying an additional 590,314 shares during the period. Global Assets Advisory LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $339,594,000. Finally, First Trust Advisors LP grew its stake in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $969.97 on Wednesday. The firm’s 50 day simple moving average is $942.67 and its 200-day simple moving average is $899.44. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a market cap of $106.46 billion, a P/E ratio of 28.65, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.